Day: March 30, 2023

LUXEMBOURG, March 30, 2023 (GLOBE NEWSWIRE) — Altisource Portfolio Solutions S.A. (“Altisource” or the “Company”) (NASDAQ: ASPS), a leading provider and marketplace for the real estate and mortgage industries, today reported financial results for the fourth quarter and full year 2022. “I am encouraged by our progress in 2022 and early 2023 as we execute on our plan to recover from the impact of the COVID-19 pandemic. In 2022, we grew revenue and Adjusted EBITDA in our countercyclical Servicer and Real Estate segment as we began to benefit from the restart of the default market, product mix and cost savings. We also grew our sales pipeline and wins, improved our Gross Profit margins to 15% from 4% and reduced our Adjusted EBITDA loss by $15 million. In February, we amended and extended our term loan and revolver to April 2025 with...

– Berdazimer gel, 10.3% (SB206) assigned PDUFA goal date of January 5, 2024 – – Strong year-over-year prescription growth across three promoted products, RHOFADE, WYNZORA and MINOLIRA – – Company to host conference call today at 8:30 a.m. ET – DURHAM, N.C., March 30, 2023 (GLOBE NEWSWIRE) — Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced its financial and operating results for the full year ended December 31, 2022 and provided a corporate update. The Company will host a conference call and webcast, today, March 30, 2023, at 8:30 a.m. ET (details below). “We have made considerable progress across all fronts over the past twelve months, which I believe sets the foundation for the future of Novan. Most notably, we submitted our New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for...

Net revenues for the fourth quarter of 2022 increased by 5.8% year-over-year to RMB626 million (US$91 million), compared with RMB592 million for the same period of 2021. Net revenues for 2022 increased by 5.4% year-over-year to RMB2,263 million (US$328 million) compared with RMB2,148 million for 2021. Net loss for the fourth quarter of 2022 was RMB83 million (US$12 million). For 2022, net income was RMB96 million (US$14 million). Adjusted net income (non-GAAP)1, which excluded share-based compensation expenses from net income (loss), for the fourth quarter of 2022 increased by 199.8% to RMB81 million (US$12 million), compared with RMB27 million for the same period of 2021. Adjusted net income (non-GAAP) for 2022 increased by 85.6% year-over-year to RMB259 million (US$38 million) compared with RMB140 million for 2021. EBITDA (non-GAAP)2...

(All figures are in Canadian dollars, unless stated otherwise. Average exchange rate in 2022: C$1.00 = R$3.97) BELO HORIZONTE, Brazil, March 30, 2023 (GLOBE NEWSWIRE) —  Verde AgriTech Plc (TSX: “NPK”) (OTCMKTS: “VNPKF”) (“Verde” or the “Company”) is pleased to announce its financial results for the full year ended December 31, 2022 (“FY 2022”) and the fourth quarter 2022 (“Q4 2022”). FY 2022 Financials        Revenue increased by 190% in FY 2022, to $80,271,000 compared to $27,709,000 in FY 2021. Revenue in Brazilian Real (“R$”) increased by 167% in FY 2022, to R$318,544,000, compared to R$119,310,000 in FY 2021. Sales of Verde’s multinutrient potassium products, BAKS® and K Forte® sold internationally as Super Greensand® (the “Product”) by volume increased by 57% in FY 2022, to 628,000 tonnes compared to 400,000...

~ U.S. Commercial Team in Place with PEDMARK® Launch Off to Solid Start Following FDA Approval of PEDMARK®in September 2022 ~ ~ Company Has Approximately $23.8 Million in Cash ~ RESEARCH TRIANGLE PARK, N.C., March 30, 2023 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today reported its financial results for the fiscal year ended December 31, 2022 and provided a business update. “It was an outstanding year for Fennec as we achieved FDA approval of PEDMARK® in the fourth quarter and evolved into a commercial-stage pharmaceutical company. For 2023, we are focused on building upon our early commercial launch momentum by continuing to execute on our strategic plans, expand our prescriber base, and increase the utilization of PEDMARK®,” said Rosty Raykov, chief executive...